Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference
Rhea-AI Summary
Phathom Pharmaceuticals (Nasdaq: PHAT) has announced its upcoming participation in the Guggenheim Securities SMID Cap Biotech Conference. The company's management team will engage in a fireside chat on Thursday, February 6, 2025, at 10:00 am ET and conduct one-on-one meetings throughout the conference, which runs from February 5-6, 2025, in New York, NY.
The biopharmaceutical company, which specializes in developing and commercializing novel treatments for gastrointestinal (GI) diseases, will provide a live webcast of the event. Interested parties can access both the live presentation and an archived recording through the Events & Presentations section of Phathom's website. The recording will remain available for 90 days after the event's conclusion.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, PHAT gained 4.80%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
FLORHAM PARK, N.J., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of the management team will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on Thursday, February 6, 2025, at 10:00 am ET.
Company management will also participate in one-on-one meetings during the conference, which will run from February 5-6, 2025, in New York, NY.
To access the live webcast and archived recording of the event, visit the Events & Presentations section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. A recording will be available for 90 days following the conclusion of the meeting.
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) that is currently marketed in the United States as VOQUEZNA® (vonoprazan) tablets for the treatment of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, in addition to VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at www.phathompharma.com and follow on LinkedIn and X.
MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com
INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com
© 2025 Phathom Pharmaceuticals. All rights reserved. VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.
FAQ
When is Phathom Pharmaceuticals (PHAT) presenting at the Guggenheim SMID Cap Biotech Conference 2025?
How long will the recording of PHAT's Guggenheim Conference presentation be available?
Where can investors watch PHAT's Guggenheim Conference presentation?
What type of meetings will PHAT management conduct at the Guggenheim Conference 2025?
What is the focus area of Phathom Pharmaceuticals' drug development?
